Ji-Youn Han

T-DXd bij HER2-overexpresserend NSCLC: DESTINY-Lung01 deel 1 resultaten

Journal of Thoracic Oncology · 23 december 2025

Olomorasib plus pembrolizumab bij KRAS G12C-gemuteerde NSCLC: werkzaamheid en veiligheid

Journal of Thoracic Oncology · 28 november 2025

Fase II Dose-Gerandomiseerde Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal ...

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 oktober 2025

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.

The New England journal of medicine · 24 juli 2025

ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab...

Clinical cancer research : an official journal of the American Association for Cancer Research · 15 november 2024

Longitudinale ctDNA voor detectie van EGFR-gemuteerd NSCLC

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2024-11

Subcutaan versus IV amivantamab plus lazertinib bij EGFR-gemuteerd NSCLC: PALOMA-3

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 oktober 2024

Atezolizumab plus bevacizumab plus chemo bij EGFR-gemuteerd NSCLC: IMpower150 subgroep

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 april 2024

Brigatinib versus crizotinib bij ALK-positief NSCLC: ALTA-1L definitieve resultaten

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021-12

Vijfjaars OS van pembrolizumab versus docetaxel bij eerder behandeld NSCLC: KEYNOTE-010 definitief

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021-10

Brigatinib versus crizotinib bij ALK-positief NSCLC: ALTA-1L definitieve PFS

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1 november 2020

Langetermijn en herbehandeling met atezolizumab bij PD-L1+ NSCLC: POPLAR/OAK analyse

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 mei 2020

Kwaliteit van leven met pembrolizumab versus docetaxel bij NSCLC: KEYNOTE-010 analyse

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2019-05

Atezolizumab doorbehandelen na progressie bij NSCLC: OAK analyse

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2018-12

Brigatinib versus crizotinib bij ALK-positief NSCLC: ALTA-1L fase III

The New England journal of medicine · 22 november 2018

CZS-werkzaamheid van osimertinib bij T790M-positief NSCLC: AURA3 analyse

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 10 september 2018

Geactualiseerde OAK-analyse: atezolizumab versus docetaxel bij gevorderd NSCLC

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2018-08

Pembrolizumab versus docetaxel bij eerder behandeld PD-L1-positief gevorderd NSCLC: KEYNOTE-010

Lancet (London, England) · 9 april 2016